- Home
- TSEM vs MRNA Comparison
TSEM vs MRNA Comparison
Compare TSEM & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TSEM | MRNA |
|---|---|---|
| Founded | 1993 | 2010 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 11.5B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | TSEM | MRNA |
|---|---|---|
| Price | $127.45 | $48.05 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 13 |
| Target Price | ★ $126.75 | $32.75 |
| AVG Volume (30 Days) | 1.4M | ★ 13.7M |
| Earning Date | 02-11-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.73 | N/A |
| Revenue | $1,513,089,000.00 | ★ $2,232,000,000.00 |
| Revenue This Year | $11.20 | N/A |
| Revenue Next Year | $17.09 | $3.18 |
| P/E Ratio | $73.46 | ★ N/A |
| Revenue Growth | ★ 8.03 | N/A |
| 52 Week Low | $28.64 | $22.28 |
| 52 Week High | $136.48 | $55.20 |
Technical Indicators
Market Signals| Indicator | TSEM | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 59.91 | 72.29 |
| Support Level | $124.00 | $46.59 |
| Resistance Level | $132.24 | $55.20 |
| Average True Range (ATR) | 5.79 | 3.00 |
| MACD | -0.07 | 1.05 |
| Stochastic Oscillator | 68.62 | 73.76 |
Price Performance
Historical ComparisonAbout TSEM Tower Semiconductor Ltd.
Tower Semiconductor Ltd is a pure-play specialty foundry that manufactures semiconductors. As a pure-play foundry, it focuses on producing integrated circuits (ICs), based on the design specifications of customers. The company's line of integrated circuits is incorporated into a range of products and markets, including consumer electronics, personal computers, communications, automotive, and industrial and medical device products. It produces ICs alongside wholly-owned subsidiaries through fabrication facilities located in Japan. The company has a geographical presence in the USA, Japan, Asia (other than Japan), and Europe.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.